Exploring the efficacy of repeated low-level red-light therapy in retarding childhood myopia progression: updated systematic review and meta-analysis

探讨重复低强度红光疗法在延缓儿童近视进展中的疗效:更新的系统评价和荟萃分析

阅读:1

Abstract

BACKGROUND: Due to the increasing prevalence of childhood myopia, low-level red-light therapy has surfaced as a non-pharmacological method to mitigate its advancement. This systematic review and meta-analysis evaluates the efficacy of repeated low-level red-light (RLRL) in pediatric populations, providing evidence-based support for its therapeutic usage. METHODS: A search was performed in PubMed, Web of Science, Cochrane Library, Embase, and prominent Chinese databases, including CNKI, VIP, and Wanfang, from their inception until May 13, 2025. This meta-analysis includes randomized controlled trials (RCTs) that matched the inclusion criteria and was analyzed using Stata software, version 18.0. RESULTS: This meta-analysis included 1,053 participants: 515 in the RLRL and 538 in the control groups. The SMD for SER reduction was 0.84 (95% CI: 0.50, 1.19), SMD for AL reduction was -1.01, (95% CI: -1.60, -0.41), and SMD for SFChT rise was 0.81 (95% CI: 0.65-0.98). There is no major publishing bias. CONCLUSION: The meta-analysis found that children with myopia who got RLRL therapy in addition to normal treatment had significantly slower disease progression than the control group. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251034037, PROSPERO 2025 CRD420251034037.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。